Next Article in Journal
Eating Behaviors in Postpartum: A Qualitative Study of Women with Obesity
Next Article in Special Issue
Bioaccessibility and Bioavailability of a Marine-Derived Multimineral, Aquamin-Magnesium
Previous Article in Journal
Oxidative Stress Levels in the Brain Are Determined by Post-Mortem Interval and Ante-Mortem Vitamin C State but Not Alzheimer’s Disease Status
Previous Article in Special Issue
TRPM6 is Essential for Magnesium Uptake and Epithelial Cell Function in the Colon
Open AccessArticle

A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias

1
Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, 1300 South 2nd Street, Suite 300, Minneapolis, MN 55454, USA
2
Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
3
Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA
4
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA
*
Author to whom correspondence should be addressed.
Nutrients 2018, 10(7), 884; https://doi.org/10.3390/nu10070884
Received: 30 May 2018 / Revised: 5 July 2018 / Accepted: 6 July 2018 / Published: 10 July 2018
(This article belongs to the Special Issue Magnesium Intake and Human Health)
Low magnesium may increase the risk of atrial fibrillation. We conducted a double-blind pilot randomized trial to assess adherence to oral magnesium supplementation (400 mg of magnesium oxide daily) and a matching placebo, estimate the effect on circulating magnesium concentrations, and evaluate the feasibility of using an ambulatory heart rhythm monitoring device (ZioPatch) for assessing premature atrial contractions. A total of 59 participants were randomized; 73% were women, and the mean age was 62 years. A total of 98% of the participants completed the follow-up. In the magnesium supplement group, 75% of pills were taken, and in the placebo group, 83% were taken. The change in magnesium concentrations was significantly greater for those given the magnesium supplements than for those given the placebo (0.07; 95% confidence interval: 0.03, 0.12 mEq/L; p = 0.002). The ZioPatch wear time was approximately 13 of the requested 14 days at baseline and follow-up. There was no difference by intervention assignment in the change in log premature atrial contractions burden, glucose, or blood pressure. Gastrointestinal changes were more common among the participants assigned magnesium (50%) than among those assigned the placebo (7%), but only one person discontinued participation. In sum, compliance with the oral magnesium supplementation was very good, and acceptance of the ZioPatch monitoring was excellent. These findings support the feasibility of a larger trial for atrial fibrillation (AF) prevention with oral magnesium supplementation. View Full-Text
Keywords: magnesium; atrial fibrillation; glucose; randomized controlled trial magnesium; atrial fibrillation; glucose; randomized controlled trial
Show Figures

Figure 1

MDPI and ACS Style

Lutsey, P.L.; Chen, L.Y.; Eaton, A.; Jaeb, M.; Rudser, K.D.; Neaton, J.D.; Alonso, A. A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias. Nutrients 2018, 10, 884.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop